Amazon enters GLP-1 at $25/mo, Kailera's $625M IPO is biotech's biggest since 2023, Perspective's alpha-PRRT hits 43% ORR, and Sapience's peptide antagonist debuts.
11 stories · Covering industry, clinical-trials, research, regulatory
Tuesday brought a market-moving pair: Amazon One Medical launched a nationwide GLP-1 program at $25/month with insurance — sending shares of Lilly, Novo Nordisk, and Hims & Hers lower — while Kailera Therapeutics priced a $625M IPO, the largest venture-backed biopharma offering since 2023. Both signal GLP-1 commercialization maturing beyond the core manufacturers. On the clinical side, AACR's Tuesday delivered strong non-GLP-1 peptide data: Perspective's alpha-emitter PRRT hit 43% ORR in neuroendocrine tumors, Sapience's ST316 β-catenin antagonist peptide showed a clean safety signal in metastatic colorectal cancer, and Asahi Kasei dosed the first patient in a PeptiDream-discovered TNFR1 antagonist Phase I. An AAN living review linked GLP-1s to 20-35% lower dementia incidence across 2M+ diabetics, while a Bloomberg editorial questioned whether RFK's peptide compounding plan gives consumers enough safety evidence ahead of July's PCAC meeting.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.
Perspective Therapeutics' [212Pb]VMT-α-NET, a first-in-class alpha-emitter peptide radionuclide therapy targeting SSTR2, achieved objective responses in 10 of 23 (43%) Cohort 2 patients with metastatic neuroendocrine tumors in Phase 1/2a data presented at AACR 2026. 18 of 25 patients (72%) remained alive without progression; no dose-limiting toxicities or Grade 4/5 adverse events observed.
Sapience Therapeutics presented first Phase 2 clinical data from ST316, a first-in-class β-catenin/BCL9 antagonist SPEAR peptide, in second-line metastatic colorectal cancer at AACR 2026. Dose expansion showed a well-tolerated safety profile with no dose-limiting toxicities or related SAEs, significant knockdown of Wnt-related signatures in tumor cells, and dose-proportional PK achieving predicted efficacious exposures.
Asahi Kasei initiated a Phase I trial in Japan of AK1940, a selective TNF receptor 1 antagonist peptide discovered jointly with PeptiDream for autoimmune and inflammatory diseases. The trial will assess PK, safety, and tolerability of single and multiple subcutaneous doses in healthy volunteers; preclinical models showed high TNFR1 selectivity and anti-inflammatory activity without blocking TNFR2 signaling.
Findings from the Oxford-led BARNARDS II study presented at ESCMID Global 2026 showed WHO-recommended ampicillin plus gentamicin first-line therapy is likely effective for only 1 in 4 neonatal sepsis infections in low- and middle-income countries. Data were collected across 13 tertiary neonatal units in Pakistan, Bangladesh, and Nigeria from February 2024 to October 2025, intensifying the case for AMR-driven peptide alternatives.
Bicycle Therapeutics presented first clinical experiences of a phage-display-derived EphA2-specific bicyclic peptide PET imaging agent in the Diagnostic Biomarkers 2 session at AACR. The imaging agent complements Bicycle's EphA2-targeted therapeutic pipeline (including nuzefatide pevedotin) and could enable patient selection for EphA2-targeted bicyclic peptide drug conjugates across multiple tumor types.
A living systematic review presented at the American Academy of Neurology 2026 Annual Meeting integrating Phase 2/3 trials and real-world data from 2+ million individuals with diabetes found GLP-1 receptor agonist use was associated with a 20-35% lower incidence of dementia versus DPP-4 or SGLT2 inhibitors. Effect was strongest for semaglutide, despite the EVOKE Phase 3 Alzheimer's trial missing its cognitive endpoint.
Novigenix presented first human clinical data at AACR 2026 from its LITOSeek AI-enabled liquid biopsy platform showing dynamic immune-transcriptomic responses in metastatic GEP-NET patients treated with either [212Pb]DOTAMTATE (AlphaMedix) alpha-emitter PRRT or [177Lu]DOTATATE (Lutathera) beta-emitter PRRT. The platform may enable treatment stratification between alpha- and beta-emitter radionuclide therapies.
A new market landscape report published April 21 projects the global peptide drug conjugate market will exceed $1.5 billion by 2031, with >14% CAGR and coverage of more than 50 peptide conjugates currently in clinical development. Commercial PDC benchmarks include Novartis's Lutathera and Pluvicto and Bicycle Therapeutics' nuzefatide pevedotin, with earlier-stage pipelines from Zymeworks, Bicycle, PeptiDream, and others.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.